Long-time Slashdot reader jhylkema writes: Just 12 people account for the lion's share of anti-vaccination propaganda posted to three of the leading social media outlets, according to a study from a London-based group opposed to online hate and disinformation. A study (PDF file) conducted by the Centre for the Countering of Digital Hate identified the "Disinformation Dozen" people, including RFK Jr., Joseph Mercola, and Sherri Tenpenny... In its study, the group blasts the social media companies for allowing their platforms to be abused and calls for them to be de-platformed.

"Living in full view of the public on the internet are a small group of individuals who... are abusing social media platforms to misrepresent the threat of Covid and spread misinformation about the safety of vaccines," the study said in its introduction. "Facebook, Google and Twitter have put policies into place to prevent the spread of vaccine misinformation; yet to date, all have failed to satisfactorily enforce those policies."
Some misinformation spreaders complain they're being censored, NPR reports, adding that "After this story published on Thursday, Facebook said it had taken down more of the accounts run by these 12 individuals."

But the study concludes anti-vaccine misinformation has already spread to an audience of 59 million followers. And yet "Analysis of a sample of anti-vaccine content that was shared or posted on Facebook and Twitter a total of 812,000 times between 1 February and 16 March 2021 shows that 65 percent of anti-vaccine content is attributable to the Disinformation Dozen...

"Analysis of anti-vaccine content posted to Facebook over 689,000 times in the last two months shows that up to 73 percent of that content originates with members of the Disinformation Dozen of leading online anti-vaxxers."

An anonymous reader quotes a report from Ars Technica: This week, the academic community provided a rather impressive example of the promise of neural implants. Using an implant, a paralyzed individual managed to type out roughly 90 characters per minute simply by imagining that he was writing those characters out by hand. Somewhere in our writing thought process, we form the intention of using a specific character, and using an implant to track this intention could potentially work. Unfortunately, the process is not especially well understood. Downstream of that intention, a decision is transmitted to the motor cortex, where it's translated into actions. Again, there's an intent stage, where the motor cortex determines it will form the letter (by typing or writing, for example), which is then translated into the specific muscle motions required to perform the action. These processes are much better understood, and they're what the research team targeted for their new work. Specifically, the researchers placed two implants in the premotor cortex of a paralyzed person. This area is thought to be involved in forming the intentions to perform movements. Catching these intentions is much more likely to produce a clear signal than catching the movements themselves, which are likely to be complex (any movement involves multiple muscles) and depend on context (where your hand is relative to the page you're writing on, etc.). With the implants in the right place, the researchers asked the participant to imagine writing letters on a page and recorded the neural activity as he did so.

Altogether, there were roughly 200 electrodes in the participant's premotor cortex. Not all of them were informative for letter-writing. But for those that were, the authors performed a principal component analysis, which identified the features of the neural recordings that differed the most when various letters were imagined. Converting these recordings into a two-dimensional plot, it was obvious that the activity seen when writing a single character always clustered together. And physically similar characters -- p and b, for example, or h, n, and r -- formed clusters near each other. (The researchers also asked the participant to do punctuation marks like a comma and question mark and used a > to indicate a space and a tilde for a period.) Overall, the researchers found they could decipher the appropriate character with an accuracy of a bit over 94 percent, but the system required a relatively slow analysis after the neural data was recorded. To get things working in real time, the researchers trained a recurrent neural network to estimate the probability of a signal corresponding to each letter.

Despite working with a relatively small amount of data (only 242 sentences' worth of characters), the system worked remarkably well. The lag between the thought and a character appearing on screen was only about half a second, and the participant was able to produce about 90 characters per minute, easily topping the previous record for implant-driven typing, which was about 25 characters per minute. The raw error rate was only about 5 percent, and applying a system like a typing autocorrect could drop the error rate down to only 1 percent. The tests were all done with prepared sentences. Once the system was validated, however, the researchers asked the participant to type out free-form answers to questions. Here, the speed went down a bit (to 75 characters a minute) and errors went up to 2 percent after autocorrection, but the system still worked. The findings have been published in the journal Nature.

An anonymous reader quotes a report from The New York Times: In an important step toward medical approval, MDMA, the illegal drug popularly known as Ecstasy or Molly, was shown to bring relief to those suffering from severe post-traumatic stress disorder when paired with talk therapy. Of the 90 people who took part in the new study, which is expected to be published later this month in Nature Medicine, those who received MDMA during therapy experienced a significantly greater reduction in the severity of their symptoms compared with those who received therapy and an inactive placebo. Two months after treatment, 67 percent of participants in the MDMA group no longer qualified for a diagnosis of PTSD, compared with 32 percent in the placebo group. MDMA produced no serious adverse side effects. Some participants temporarily experienced mild symptoms like nausea and loss of appetite.

Before MDMA-assisted therapy can be approved for therapeutic use, the Food and Drug Administration needs a second positive Phase 3 trial, which is currently underway with 100 participants. Approval could come as early as 2023. Mental health experts say that this research -- the first Phase 3 trial conducted on psychedelic-assisted therapy -- could pave the way for further studies on MDMA's potential to help address other difficult-to-treat mental health conditions, including substance abuse, obsessive compulsive disorder, phobias, eating disorders, depression, end-of-life anxiety and social anxiety in autistic adults. And, mental health researchers say, these studies could also encourage additional research on other banned psychedelics, including psilocybin, LSD and mescaline. "This is a wonderful, fruitful time for discovery, because people are suddenly willing to consider these substances as therapeutics again, which hasn't happened in 50 years," said Jennifer Mitchell, a neuroscientist at the University of California, San Francisco, and lead author of the new study.

The Food and Drug Administration on Monday approved Pfizer and BioNTech's request to allow their Covid-19 vaccine to be given to kids ages 12 to 15 on an emergency use basis, allowing states to get middle school students vaccinated before the fall. The two-dose vaccine is already authorized for use in people 16 and older. CNBC reports: Acting FDA Commissioner Dr. Janet Woodcock said the decision brings "us closer to returning to a sense of normalcy and to ending the pandemic." She assured parents that the agency "undertook a rigorous and thorough review of all available data" before clearing it for use in the teens. The companies said in late March that the vaccine was found to be 100% effective in a clinical trial of more than 2,000 adolescents. They also said the vaccine elicited a "robust" antibody response in the children, exceeding those in an earlier trial of older teens and young adults. Side effects were generally consistent with those seen in adults, they added.

Vaccinating children is seen as crucial to ending the pandemic. The nation is unlikely to achieve herd immunity -- when enough people in a given community have antibodies against a specific disease -- until children can get vaccinated, health officials and experts say. Children make up around 20% of the total U.S. population, according to government data. Between 70% and 85% of the U.S. population needs to be vaccinated against Covid to achieve herd immunity, experts say, and some adults may refuse to get the shots. Though more experts now say herd immunity is looking increasingly unlikely as variants spread. The report notes that the same two-dose regimen that's use for people 16 years of age and older will also be used for kids ages 12 to 15. FDA approval for kids under age 12 could come in the second half of the year.

CNN reports that a new study has again found that Mediterranean diets can lower your risk of dementia "by interfering with the buildup of two proteins, amyloid and tau, into the plaques and tangles that are hallmarks of Alzheimer's disease." "The mountain of evidence continues to build that you are what you eat when it comes to brain health," said Dr. Richard Isaacson, who directs the Alzheimer's Prevention Clinic at Weill Cornell Medicine and New York-Presbyterian Hospital... "For every point of higher compliance with the diet, people had one extra year less of brain aging. That is striking," Isaacson added. "Most people are unaware that it's possible to take control of your brain health, yet this study shows us just that...."

What is the Mediterranean diet...? The true diet is simple, plant-based cooking, with the majority of each meal focused on fruits and vegetables, whole grains, beans and seeds, with a few nuts and a heavy emphasis on extra-virgin olive oil. Fats other than olive oil, such as butter, are consumed rarely, if at all. And say goodbye to refined sugar or flour. Meat can make a rare appearance, but usually only to flavor a dish. Instead, meals may include eggs, dairy and poultry, but in much smaller portions than in the traditional Western diet. However, fish, which are full of brain-boosting omega-3's, are a staple.

The study, published Wednesday in Neurology, the medical journal of the American Academy of Neurology, examined 343 people at high risk of developing Alzheimer's and compared them to 169 cognitively normal subjects... After adjusting for factors like age, sex and education, the study found that people who did not follow the diet closely had more signs of amyloid and tau buildup in their spinal fluid than those who did adhere to the diet... "These results add to the body of evidence that show what you eat may influence your memory skills later on," said study author Tommaso Ballarini, a postdoctoral fellow at the German Center for Neurodegenerative Diseases in Bonn, Germany, in a statement...

This isn't the first research to find a link between brain health and the Mediterranean diet or one of its plant-based cousins. A study of nearly 6,000 healthy older Americans with an average age of 68 found those who followed the Mediterranean or the similar MIND diet lowered their risk of dementia by a third.
After reviewing the new study, Isaacson told CNN that "The strongest factor to really move the needle was regular fish consumption."

"An XKCD comic — and its many remixes — perfectly captures the absurdity of academic research," writes the Atlantic (in an article shared by Slashdot reader shanen).

It argues that the cartoon "captured the attention of scientists — and inspired many to create versions specific to their own disciplines. Together, these became a global, interdisciplinary conversation about the nature of modern research practices." It depicts a taxonomy of the 12 "Types of Scientific Paper," presented in a grid. "The immune system is at it again," one paper's title reads. "My colleague is wrong and I can finally prove it," declares another. The gag reveals how research literature, when stripped of its jargon, is just as susceptible to repetition, triviality, pandering, and pettiness as other forms of communication. The cartoon's childlike simplicity, though, seemed to offer cover for scientists to critique and celebrate their work at the same time...

You couldn't keep the biologists away from the fun ("New microscope!! Yours is now obsolete"), and — in their usual fashion — the science journalists soon followed ("Readers love animals"). A doctoral student cobbled together a website to help users generate their own versions. We reached Peak Meme with the creation of a meta-meme outlining a taxonomy of academic-paper memes. At that point, the writer and internet activist Cory Doctorow lauded the collective project of producing these jokes as "an act of wry, insightful auto-ethnography — self-criticism wrapped in humor that tells a story."

Put another way: The joke was on target. "The meme hits the right nerve," says Vinay Prasad, an associate epidemiology professor and a prominent critic of medical research. "Many papers serve no purpose, advance no agenda, may not be correct, make no sense, and are poorly read. But they are required for promotion." The scholarly literature in many fields is riddled with extraneous work; indeed, I've always been intrigued by the idea that this sorry outcome was more or less inevitable, given the incentives at play. Take a bunch of clever, ambitious people and tell them to get as many papers published as possible while still technically passing muster through peer review ... and what do you think is going to happen? Of course the system gets gamed: The results from one experiment get sliced up into a dozen papers, statistics are massaged to produce more interesting results, and conclusions become exaggerated. The most prolific authors have found a way to publish more than one scientific paper a week. Those who can't keep up might hire a paper mill to do (or fake) the work on their behalf.
The article argues the Covid-19 pandemic induced medical journals to forego papers about large-scale clinical trials while "rapidly accepting reports that described just a handful of patients. More than a few CVs were beefed up along the way."

But pandemic publishing has only served to exacerbate some well-established bad habits, Michael Johansen, a family-medicine physician and researcher who has criticized many studies as being of minimal value, told me. "COVID publications appear to be representative of the literature at large: a few really important papers and a whole bunch of stuff that isn't or shouldn't be read."
Unfortunately, the Atlantic adds, "none of the scientists I talked with could think of a realistic solution."

CNN recently reported on "a batch" of new studies published Wednesday — with one quantifying how much immunity improves after the second dose, and others showing how well coronavirus vaccines work against new variants of the virus: The first nationwide study of coronavirus vaccination, done in Israel, showed Pfizer/BioNtech's vaccine works far better after two doses. Two shots of the vaccine provided greater than 95% protection from infection, severe illness and death, Dr. Eric Haas of the Israel Ministry of Health and colleagues reported in the Lancet medical journal. "Two doses of BNT162b2 are highly effective across all age groups in preventing symptomatic and asymptomatic SARS-CoV-2 infections and COVID-19-related hospitalizations, severe disease, and death, including those caused by the B.1.1.7 SARS-CoV-2 variant," they wrote. The B.1.1.7 variant, first seen in Britain, has spread widely and is now the most common new variant seen in the US. It was also common in Israel when the study was done...

"By 14 days after vaccination, protections conferred by a second dose [of the Pfizer vaccine] increased to 96.5% protection against infection, 98% against hospitalization, and 98.1% against death," the team wrote. But people who got only one dose of the vaccine were far less protected. One dose alone gave just 57.7% protection against infection, 75.7% against hospitalization, and 77% against death....

Separately, a team in the Gulf state of Qatar looked at the efficacy of Pfizer's vaccine in the population there when B.1.351 and B.1.1.7 were both circulating. They found reassuring results. "The estimated effectiveness of the vaccine against any documented infection with the B.1.1.7 variant was 89.5% at 14 or more days after the second dose. The effectiveness against any documented infection with the B.1.351 variant was 75%," the researchers wrote in a letter to the New England Journal of Medicine...

Vaccine maker Moderna reported Wednesday that a booster shot delivering a half-dose of its current vaccine revs up the immune response against both B.1.351 and P.1. And a booster dose formulated specifically to match B.1.351 was even more effective, Moderna said in a statement...

In another study, vaccine maker Novavax confirmed earlier findings that showed its vaccine protects against B.1.351.

AmiMoJo shares a report from the BBC: The World Health Organization (WHO) has granted emergency approval for the Covid vaccine made by Chinese state-owned company Sinopharm. It is the first vaccine developed by a non-Western country to get WHO backing. The vaccine has already been given to millions of people in China and elsewhere. The WHO had previously only approved the vaccines made by Pfizer, AstraZeneca, Johnson & Johnson and Moderna.

With little data released internationally early on, the effectiveness of the various Chinese vaccines has long been uncertain. But the WHO on Friday said it had validated the "safety, efficacy and quality" of the Sinopharm jab. The WHO said the addition of the vaccine had "the potential to rapidly accelerate Covid-19 vaccine access for countries seeking to protect health workers and populations at risk." It is recommending that the vaccine be administered in two doses to those aged 18 and over. A decision is expected in the coming days on another Chinese vaccine developed by Sinovac, while Russia's Sputnik vaccine is under assessment.

An anonymous reader quotes a report from The New York Times: Federal health officials on Friday updated public guidance about how the coronavirus spreads, emphasizing that transmission occurs by inhaling very fine respiratory droplets and aerosolized particles, as well as through contact with sprayed droplets or touching contaminated hands to one's mouth, nose or eyes. The Centers for Disease Control and Prevention now states explicitly -- in large, bold lettering -- that airborne virus can be inhaled even when one is more than six feet away from an infected individual. The new language, posted online, is a change from the agency's previous position that most infections were acquired through "close contact, not airborne transmission."

As the pandemic unfolded last year, infectious disease experts warned for months that both the C.D.C. and the World Health Organization were overlooking research that strongly suggested the coronavirus traveled aloft in small, airborne particles. Several scientists on Friday welcomed the agency's scrapping of the term "close contact," which they criticized as vague and said did not necessarily capture the nuances of aerosol transmission. "C.D.C. has now caught up to the latest scientific evidence, and they've gotten rid of some old problematic terms and thinking about how transmission occurs," said Linsey Marr, an aerosol expert at Virginia Tech. The new focus underscores the need for the federal Occupational Safety and Health Administration to issue standards for employers to address potential hazards in the workplace, some experts said.

The German company CureVac hopes its RNA vaccine will rival those made by Moderna and Pfizer-BioNTech. It could be ready next month. From a report: In early 2020, dozens of scientific teams scrambled to make a vaccine for Covid-19. Some chose tried-and-true techniques, such as making vaccines from killed viruses. But a handful of companies bet on a riskier method, one that had never produced a licensed vaccine: deploying a genetic molecule called RNA. The bet paid off. The first two vaccines to emerge successfully out of clinical trials, made by Pfizer-BioNTech and by Moderna, were both made of RNA. They both turned out to have efficacy rates about as good as a vaccine could get. In the months that followed, those two RNA vaccines have provided protection to tens of millions of people in some 90 countries. But many parts of the world, including those with climbing death tolls, have had little access to them, in part because they require being kept in a deep freeze.

Now a third RNA vaccine may help meet that global need. A small German company called CureVac is on the cusp of announcing the results of its late-stage clinical trial. As early as next week, the world may learn whether its vaccine is safe and effective. CureVac's product belongs to what many scientists refer to as the second wave of Covid-19 vaccines that could collectively ease the world's demand. Novavax, a company based in Maryland whose vaccine uses coronavirus proteins, is expected to apply for U.S. authorization in the next few weeks. In India, the pharmaceutical company Biological E is testing another protein-based vaccine that was developed by researchers in Texas. In Brazil, Mexico, Thailand and Vietnam, researchers are starting trials for a Covid-19 shot that can be mass-produced in chicken eggs. Vaccines experts are particularly curious to see CureVac's results, because its shot has an important advantage over the other RNA vaccines from Moderna and Pfizer-BioNTech. While those two vaccines have to be kept in a deep freezer, CureVac's vaccine stays stable in a refrigerator -- meaning it could more easily deliver the newly discovered power of RNA vaccines to hard-hit parts of the world.

President Biden threw his support behind a World Trade Organization proposal earlier this week to waive intellectual property protections for COVID-19 vaccines, clearing a hurdle for vaccine-strapped countries to manufacture their own vaccines even though the patents are privately held. From a report: "This is a global health crisis, and the extraordinary circumstances of the COVID-19 pandemic call for extraordinary measures," U.S. trade representative Katherine Tai said in a statement. "The Administration believes strongly in intellectual property protections, but in service of ending this pandemic, supports the waiver of those protections for COVID-19 vaccines." The pace of vaccinating against COVID-19 in the U.S. is slowing down. In some places, there are more vaccine doses than people who want them. Meanwhile, India is now the epicenter of the pandemic, and just 2% of its population is fully vaccinated. The WTO is considering a proposal to address that inequity, as India, South Africa and over 100 other nations advocate to waive IP rights for COVID-19 vaccines and medications, which could let manufacturers in other countries make their own.

An anonymous reader quotes a report from the BBC: There remains "little association" between technology use and mental-health problems, a study of more than 430,000 10 to 15-year-olds suggests. The Oxford Internet Institute compared TV viewing, social-media and device use with feelings of depression, suicidal tendencies and behavioral problems. It found a small drop in association between depression and social-media use and TV viewing, from 1991 to 2019. There was a small rise in that between emotional issues and social-media use. "We couldn't tell the difference between social-media impact and mental health in 2010 and 2019," study co-author Prof Andrew Przybylski. said. "We're not saying that fewer happy people use more social media. We're saying that the connection is not getting stronger." The paper is published in the journal Clinical Psychological Science.

The Apple Watch may gain the ability to measure blood pressure, blood glucose, and blood alcohol levels, according to newly-revealed information about one of Apple's chosen business partners. MacRumors reports: Apple has been revealed to be the largest customer of the British electronics start-up Rockley Photonics, The Telegraph reports. Rockley Photonics has developed non-invasive optical sensors for detecting multiple blood-related health metrics, including blood pressure, blood glucose, and blood alcohol levels, many of which are only normally detectable with more invasive dedicated medical equipment. Rockley's sensors beam infrared light through a user's skin, much like the existing sensors on the back of the Apple Watch for detecting heart rate and blood oxygen levels.

Rockley's disclosure that its biggest client is Apple came about as the company prepares to go public in New York. The company's filings said that Apple accounted for the majority of its revenue over the last two years and that it has an ongoing "supply and development agreement" with the company, under which it expects to continue to heavily rely on Apple for most of its revenue. Given the growth of Rockley Photonics and the scale of Apple's partnership with the company, it seems to be virtually inevitable that the company's health sensor technology will be coming to the Apple Watch sooner rather than later.

Scientific American has published an opinion piece by the principle investigator for a project called SPARK, launched five years ago "to harness the power of big data by engaging hundreds of thousands of individuals with autism and their family members to participate in research."

The article calls autism "a remarkably heterogeneous disorder that affects more than five million Americans and has no FDA-approved treatments," arguing that the more people who participate in their research, "the deeper and richer these data sets become, catalyzing research that is expanding our knowledge of both biology and behavior to develop more precise approaches to medical and behavioral issues." SPARK is the world's largest autism research study to date with over 250,000 participants, more than 100,000 of whom have provided DNA samples through the simple act of spitting in a tube. We have generated genomic data that have been de-identified and made available to qualified researchers. SPARK has itself been able to analyze 19,000 genes to find possible connections to autism; worked with 31 of the nation's leading medical schools and autism research centers; and helped thousands of participating families enroll in nearly 100 additional autism research studies.

Genetic research has taught us that what we commonly call autism is actually a spectrum of hundreds of conditions that vary widely among adults and children. Across this spectrum, individuals share core symptoms and challenges with social interaction, restricted interests and/or repetitive behaviors. We now know that genes play a central role in the causes of these "autisms," which are the result of genetic changes in combination with other causes including prenatal factors. To date, research employing data science and machine learning has identified approximately 150 genes related to autism, but suggests there may be as many as 500 or more...

But in order to get answers faster and be certain of these results, SPARK and our research partners need a huge sample size: "bigger data." To ensure an accurate inventory of all the major genetic contributors, and learn if and how different genetic variants contribute to autistic behaviors, we need not only the largest but also the most diverse group of participants. The genetic, medical and behavioral data SPARK collects from people with autism and their families is rich in detail and can be leveraged by many different investigators. Access to rich data sets draws talented scientists to the field of autism science to develop new methods of finding patterns in the data, better predicting associated behavioral and medical issues, and, perhaps, identifying more effective supports and treatments...

We know that big data, with each person representing their unique profile of someone impacted by autism, will lead to many of the answers we seek.

Artem S. Tashkinov shares a report from Ars Technica: Health regulators in Brazil say that doses of Russia's Sputnik V COVID-19 vaccine contain a cold-causing virus capable of replicating in human cells. The unintended presence of the virus in the vaccine can "lead to infections in humans and can cause damage and death, especially in people with low immunity and respiratory problems, among other health problems," Brazil's Health Regulatory Agency, Anvisa, said Wednesday in a translated statement. Russia has unequivocally denied the claim, lobbed legal threats at Anvisa, and accused the respected regulators of being politically motivated to reject the vaccine. Still, Brazil's findings raise serious questions about the quality and safety of the vaccine, which is now being used in many countries. The findings also support concerns of Slovak regulators, who said earlier this month that batches of Sputnik V they received did not "have the same characteristics and properties" as the Sputnik V vaccine that was described in a peer-reviewed publication and found to be 91.6 percent effective.

Moreover, quality-control issues weren't the end of Anvisa's concerns. In an overall evaluation of the Russian vaccine, Brazil's regulators found its safety and efficacy were based on insufficient, limited, and sometimes faulty data and analyses. "Flaws... were identified in all stages of clinical studies," Anvisa said. The agency also reported that its inspectors who traveled to Russia to assess the vaccine's production were barred from vaccine facilities at Gamaleya Institute, which developed Sputnik V. Russia touts that "the safety and efficacy of Sputnik V has been confirmed by 61 regulators in countries where the vaccine has been authorized." However, Brazil's regulators said that of the 51 countries it contacted, only 14 were using the vaccine, and most of those countries did not have a tradition of vigilant drug-safety monitoring.

An anonymous reader quotes a report from Scientific American: Since the novel coronavirus began its global spread, influenza cases reported to the World Health Organization have dropped to minuscule levels. The reason, epidemiologists think, is that the public health measures taken to keep the coronavirus from spreading also stop the flu. Influenza viruses are transmitted in much the same way as SARS-CoV-2, but they are less effective at jumping from host to host. As Scientific American reported last fall, the drop-off in flu numbers was both swift and universal. Since then, cases have stayed remarkably low. "There's just no flu circulating," says Greg Poland, who has studied the disease at the Mayo Clinic for decades. The U.S. saw about 600 deaths from influenza during the 2020-2021 flu season. In comparison, the Centers for Disease Control and Prevention estimated there were roughly 22,000 deaths in the prior season and 34,000 two seasons ago.

Because each year's flu vaccine is based on strains that have been circulating during the past year, it is unclear how next year's vaccine will fare, should the typical patterns of the disease return. [...] Public health experts are grateful for the reprieve. Some are also worried about a lost immune response, however. If influenza subsides for several years, today's toddlers could miss a chance to have an early-age response imprinted on their immune system. That could be good or bad, depending on what strains circulate during the rest of their life. For now, future flu transmission remains a roll of the dice.

Americans who have been fully vaccinated against COVID-19 can safely do many outdoor activities without wearing a mask, according to updated guidance Tuesday from the US Centers for Disease Control and Prevention. However, health officials said vaccinated people should continue to wear a mask indoors and at crowded outdoor events, such as concerts, parades and sports events. From a report: "There are many situations where fully vaccinated people do not need to wear a mask, particularly if they are outdoors," said CDC Director Dr. Rochelle Walensky during a press briefing. "If you are fully vaccinated and want to attend a small outdoor gathering with people who are vaccinated and unvaccinated or dine at an outdoor restaurant with friends form multiple households, the science shows -- if you're vaccinated -- you can do so safely unmasked."

The CDC released a graphic to help people make decisions about when to wear a mask both outdoors and indoors. For fully vaccinated people, the CDC says these outdoor activities are safe without a mask: Walk, run or bike outdoors with members of your household. Attend a small, outdoor gathering with fully vaccinated family and friends. Attend a small, outdoor gathering with fully vaccinated and unvaccinated people. Dine at an outdoor restaurant with friends from multiple households.

HealthDay reports: There's no evidence of genetic damage in the children of parents who were exposed to radiation from the 1986 Chernobyl Nuclear Power Plant disaster in Ukraine, researchers say.

Several previous studies have examined the risks across generations of radiation exposure from events such as this, but have yielded inconclusive results. In this study, the investigators analyzed the genomes of 130 children and parents from families where one or both parents were exposed to radiation due to the Chernobyl accident, and where children were conceived afterward and born between 1987 and 2002.

There was no increase in gene changes in reproductive cells of study participants, and rates of new germline mutations were similar to those in the general population, according to a team led by Meredith Yeager of the U.S. National Cancer Institute, in Rockville, Md.

An anonymous reader shares an excerpt from a Science Magazine blog, written by Derek Lowe: Excellent news today: we have word of the most effective malaria vaccine yet discovered. A year-long trial in Burkina Faso has shown 77% efficacy, which is by far the record, and which opens the way to potentially relieving a nearly incalculable burden of disease and human suffering.

This new vaccine (R21) uses a circumsporozoite protein (CSP) antigen -- that's a highly conserved protein of the parasite, involved in several functions as the parasite makes the move from mosquito to human and into different human tissues such as the salivary glands. This has been a vaccine ingredient before, such as in the RTS,S vaccine (the first one ever licensed), but R21 has a much higher proportion of CSP assembled into a virus-like particle. It also uses the exact same adjuvant from Novavax (Matrix-M) that they are using in their coronavirus vaccine -- you can't keep a good adjuvant down, and this Chilean-soapbark-based one seems to really kick the immune system up under all circumstances.

The higher-adjuvant cohort showed 77% vaccine efficacy, and the lower-adjuvant one showed 74% with (as you'd expect) overlapping confidence intervals. The first group had significantly higher antibody levels, though, and they're currently doing an additional year of follow-up to see how long the protection lasts and if these doses differentiate themselves. The antibody levels at the one-year mark in both groups were significantly higher than with the RTS,S vaccine, and in particular, antibodies against the repeat section in the middle of the circumsporozite protein seemed to correlate strongly with protection. No safety problems so far. The team is now planning a larger Phase III at five different African site, with varying seasonality and malaria loads.

India reported a global record of more than 314,000 new infections Thursday as a grim coronavirus surge hits the world's second-most populous country, sending more and more sick people into a fragile health care system critically short of hospital beds and oxygen. From a report: The 314,835 infections added in the past 24 hours raise India's total past 15.9 million cases since the pandemic began. It's the second-highest total in the world next to the United States. India has nearly 1.4 billion people. A large number of hospitals are reporting acute shortages of beds and medicine and are running on dangerously low levels of oxygen. The New Delhi High Court on Wednesday ordered the government to divert oxygen from industrial use to hospitals to save people's lives.

"You can't have people die because there is no oxygen. Beg, borrow or steal, it is a national emergency," the judges said responding to a petition by a New Delhi hospital seeking its intervention. The government is rushing oxygen tankers to replenish supplies to hospitals. India's Health Minister Harsh Vardhan said on Thursday that "demand and supply is being monitored round the clock." He said in a tweet that to address the exponential spike in demand, the government has increased the quota of oxygen for the worst-hit seven states. The surge has brought pain, fear and agony to many lives in New Delhi and other cities. In scenes familiar across the country, ambulances are seen rushing from one hospital to another, trying to find an empty bed. Grieving relatives are lining up outside crematoriums where the arrival of dead bodies has jumped several times.